-
公开(公告)号：US20230303719A1
公开(公告)日：2023-09-28
申请号：US18177571
申请日：2023-03-02
申请人： YALE UNIVERSITY , GENNAO BIO, INC.
发明人： Elias Quijano , Peter Glazer , Stephen Squinto , Dale Ludwig
CPC分类号： C07K16/44 , A61K47/6843 , A61K39/39583 , A61P35/02 , A61K38/1793 , A61P1/18 , A61K2039/505
摘要： The disclosure provides humanized 3E10 antibodies and antigen binding fragments thereof. Compositions and methods of using the humanized 3E10 antibodies and antigen binding fragments thereof to deliver cargo are also disclosed.
-
公开(公告)号：US20170340728A1
公开(公告)日：2017-11-30
申请号：US15633589
申请日：2017-06-26
IPC分类号： A61K39/215 , C07K14/165 , G01N33/569 , C12N7/00 , A61K38/00
CPC分类号： A61K39/215 , A61K38/00 , A61K39/12 , A61K39/39583 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K14/165 , C07K16/10 , C07K2317/21 , C07K2317/30 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N7/00 , C12N2770/20022 , C12N2770/20034 , G01N33/569
摘要： The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome—Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
-
公开(公告)号：US20170281807A1
公开(公告)日：2017-10-05
申请号：US15504512
申请日：2015-08-24
IPC分类号： A61K51/10 , G01N33/68 , G01N33/53 , A61K39/395 , C07K16/18
CPC分类号： A61K39/39583 , A61K38/1716 , A61K39/395 , A61K47/66 , A61K47/6891 , A61K51/10 , A61K2039/505 , A61K2039/545 , C07K14/4711 , C07K16/18 , C07K2317/34 , C07K2319/00 , C07K2319/70 , G01N33/53 , G01N33/6896 , G01N2333/4709
摘要： Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive fusion peptide contains an epitope of a known antibody. When the fusion peptide is administered to a subject, the fusion peptide binds amyloids in the subject. Administration to the subject of the known antibody that binds the epitope of the fusion peptide then targets the antibody to the amyloid deposit to which the fusion peptide is bound.
-
公开(公告)号：US20160376353A1
公开(公告)日：2016-12-29
申请号：US15196195
申请日：2016-06-29
发明人： Robyn J. Puro
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , A61K39/39583 , A61K2039/505 , C07K2317/14 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/71 , C07K2317/76 , C07K2317/92
摘要： The present invention encompasses humanized antibodies that specifically bind N2 peptide, methods for the preparation thereof and methods for the use thereof.
摘要翻译： 本发明包括特异性结合N2肽的人源化抗体，其制备方法及其使用方法。
-
5.发明申请TREATMENT OF CELIAC DISEASE, C. DIFFICILE INFECTION, FOOD INTOLERANCE AND FOOD ALLERGY WITH SECRETORY IgA/IgM 审中-公开治疗CELIAC疾病，C.差异感染，食物不耐受和食物过敏与秘密IgA / IgM公开(公告)号：US20160319039A1
公开(公告)日：2016-11-03
申请号：US15205359
申请日：2016-07-08
申请人： Michael R. Simon
发明人： Michael R. Simon
CPC分类号： C07K16/44 , A61K9/0053 , A61K38/14 , A61K39/39583 , A61K39/40 , A61K2039/505 , A61K2039/507 , A61K2039/542 , A61K2039/577 , C07K16/00 , C07K16/1282 , C07K16/16 , C07K16/18 , C07K2317/75 , C07K2317/76 , G02F1/167 , G02F2001/133388 , G06F3/147 , G09G2310/0232 , G09G2340/04 , G09G2340/0407 , G09G2380/14
摘要： A process is provided for inhibiting symptoms of celiac disease, Clostridium difficile associated diseases such as Clostridium difficile colitis, pseudomembranous colitis and antibiotic associated diarrhea, food allergy or food intolerance in a subject that includes the oral adminstration to the subject suffering from food allergy or food intolerance an IgM. When administered in a, therapeutic quantity based on the subject characteristics and the type of IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgM are effective when administered orally.
摘要翻译： 提供了一种抑制肠道疾病症状的方法，艰难梭菌相关疾病如难辨梭状芽孢杆菌结肠炎，假膜性结肠炎和抗生素相关性腹泻，食物过敏或食物不耐受性，包括对患有食物过敏或食物的受试者的口服 不耐受的IgM。 当基于受试者特征和IgM的类型以治疗量施用时，该受试者的食物过敏症或食物不耐受症状被抑制。 即使非分泌形式的IgM在口服给药时也是有效的。
-
公开(公告)号：US20160243230A1
公开(公告)日：2016-08-25
申请号：US15052772
申请日：2016-02-24
IPC分类号： A61K39/395 , A61K38/17
CPC分类号： A61K39/39583 , A61K38/1716 , A61K39/395 , A61K47/66 , A61K47/6891 , A61K51/10 , A61K2039/505 , A61K2039/545 , C07K14/4711 , C07K16/18 , C07K2317/34 , C07K2319/00 , C07K2319/70 , G01N33/53 , G01N33/6896 , G01N2333/4709
摘要： Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive fusion peptide contains an epitope of a known antibody. When the fusion peptide is administered to a subject, the fusion peptide binds amyloids in the subject. Administration to the subject of the known antibody that binds the epitope of the fusion peptide then targets the antibody to the amyloid deposit to which the fusion peptide is bound.
摘要翻译： 公开了用于靶向淀粉样沉积物的抗体的方法和组合物。 例如，将淀粉样蛋白沉积物结合的淀粉样蛋白反应性肽施用于受试者。 然后向受试者施用淀粉样蛋白反应肽的抗体。 在施用抗体时，淀粉样蛋白反应肽结合抗体，因此预先将抗体靶向淀粉样沉积物。 在其他实例中，淀粉样蛋白反应性融合肽含有已知抗体的表位。 当向对象施用融合肽时，融合肽结合受试者中的淀粉样蛋白。 对结合融合肽的表位的已知抗体的受试者的给药然后靶向与融合肽结合的淀粉样蛋白沉积物的抗体。
-
公开(公告)号：US09303090B2
公开(公告)日：2016-04-05
申请号：US12701128
申请日：2010-02-05
申请人： Oleg Iliich Epshtein
发明人： Oleg Iliich Epshtein
CPC分类号： C07K16/44 , A61K31/277 , A61K39/39583 , A61K41/0004 , A61K2039/505 , A61K2039/545 , C07K16/00 , C07K16/22 , C07K16/24 , C07K16/241 , C07K16/243 , C07K16/245 , C07K16/246 , C07K16/248 , C07K16/249 , C07K16/26 , C07K16/28 , C07K16/2806 , C07K16/40 , C07K2317/73 , C07K2317/75 , C07K2317/77
摘要： A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome.
摘要翻译： 治疗病理综合征的方法包括向抗原施用超低剂量抗体的活化形式，其中所述活化形式通过反复连续稀释与外部冲击结合获得，并且所述抗原是施用的物质或药剂 影响这种特殊病理综合征的形成机制。
-
公开(公告)号：US09273117B2
公开(公告)日：2016-03-01
申请号：US12701197
申请日：2010-02-05
申请人： Oleg Iliich Epshtein
发明人： Oleg Iliich Epshtein
CPC分类号： C07K16/44 , A61K31/277 , A61K39/39583 , A61K41/0004 , A61K2039/505 , A61K2039/545 , C07K16/00 , C07K16/22 , C07K16/24 , C07K16/241 , C07K16/243 , C07K16/245 , C07K16/246 , C07K16/248 , C07K16/249 , C07K16/26 , C07K16/28 , C07K16/2806 , C07K16/40 , C07K2317/73 , C07K2317/75 , C07K2317/77
摘要： The invention provides for a method of treating neuropsychiatric disorders in a patient. The method comprises the step of administering to the patient a homeopathically potentized form of at least one antibody to an antigen capable of treating the neuropsychiatric disorders.
摘要翻译： 本发明提供了治疗患者神经精神障碍的方法。 该方法包括向患者施用对能够治疗神经精神障碍的抗原的至少一种抗体的顺势疗效强化形式的步骤。
-
公开(公告)号：US20160025745A1
公开(公告)日：2016-01-28
申请号：US14814238
申请日：2015-07-30
申请人： Jia Guo , Xin Lin , Steve Georas , Patricia Sime
发明人： Jia Guo , Xin Lin , Steve Georas , Patricia Sime
IPC分类号： G01N33/68 , A61K38/44 , A61K31/713 , C12Q1/68
CPC分类号： G01N33/6875 , A61K31/7088 , A61K31/713 , A61K38/44 , A61K39/395 , A61K39/39533 , A61K39/39583 , A61K45/00 , C12Q1/6883 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/154 , C12Q2600/158 , C12Y114/11027 , G01N2800/10 , G01N2800/52
摘要： The present invention is directed to methods of diagnosing and treating a fibrotic condition in a mammalian subject. These methods involve measuring the levels of trimethylation at lysine residue 27 of histone-3 and/or measuring the expression levels of EZH2 or YY-1. Agents useful for treating fibrosis or a fibrotic condition are also disclosed.
摘要翻译： 本发明涉及在哺乳动物受试者中诊断和治疗纤维化病症的方法。 这些方法包括测量组蛋白-3的赖氨酸残基27处的三甲基化水平和/或测量EZH2或YY-1的表达水平。 还公开了可用于治疗纤维化或纤维化病症的药剂。
-
公开(公告)号：US20160017035A1
公开(公告)日：2016-01-21
申请号：US14379879
申请日：2013-02-20
发明人： Ali Amara , Laurent Meertens
IPC分类号： C07K16/28 , C07K14/705 , A61K38/17 , A61K31/713 , A61K45/06 , A61K39/395 , C12N15/113 , C07K16/44
CPC分类号： C07K16/2803 , A61K31/713 , A61K38/1774 , A61K39/3955 , A61K39/39583 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K14/70503 , C07K16/2863 , C07K16/44 , C07K2317/76 , C07K2319/30 , C12N15/1138 , C12N2310/111 , C12N2310/14 , Y02A50/383 , Y02A50/386 , Y02A50/388 , Y02A50/394
摘要： The present invention concerns the use of an inhibitor of an interaction between phosphatidylserine and a TIM receptor for preventing or treating a virus entry cofactors, in particular phosphatidylserine harboring virus infection such as flavivirus infection.
摘要翻译： 本发明涉及磷脂酰丝氨酸与TIM受体之间的相互作用抑制剂用于预防或治疗病毒进入辅因子，特别是含有病毒感染如黄病毒感染的磷脂酰丝氨酸的用途。
-
-
-
-
-
-
-
-
-
搜索结果
136 条记录 (耗时 0.026 秒)
